Drugs Made In America Acq... (DMAA)
NasdaqGM: DMAA
· Real-Time Price · USD
10.69
+0.00 (0.00%)
At close: Aug 10, 2026, 3:54 PM
Drugs Made In America Acquisition Corp. (DMAA) Stock Price, Analysis & Data
0.00% (1D)
| Bid | 10.65 |
| Market Cap | 259.52M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | 6.66M |
| Beta | n/a |
| EPS (ttm) | 0.2 |
| PE Ratio (ttm) | 53.45 |
| Forward PE | n/a |
| P/B (ttm) | -48.81 |
| P/S (ttm) | n/a |
| Earnings Date | n/a |
| Ask | 10.54 |
| Volume | 6 |
| Avg. Volume (20D) | 35,238 |
| Open | 10.69 |
| Previous Close | 10.69 |
| Day's Range | 10.69 - 10.69 |
| 52-Week Range | 10.22 - 10.72 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About DMAA
Drugs Made In America Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combinations with one or more businesses. Drugs Made In America Acquisition Corp. was incorporated in 2024 and is based in New York, New York....
Industry Shell Companies
Sector Financial Services
IPO Date Feb 25, 2025
Employees n/a
Stock Exchange NasdaqGM
Ticker Symbol DMAA
Financial Performance
In 2025, Drugs Made In America Acquisition's revenue was 0, an increase of undefined% compared to the previous year's n/a. Earnings were 5.94M, an increase of undefined%.
Financial Statements